Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Implant or insert
Reissue Patent
1997-08-22
2004-10-19
Page, Thurman K. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Implant or insert
C424S400000, C424S489000, C424S451000, C424S427000
Reissue Patent
active
RE038628
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to methods of treatment and to novel pharmaceutical compositions for use in such methods.
DESCRIPTION OF THE PRIOR ARTS
In British Patent No 2022078 there are disclosed a number of pyranoquinoline compounds which are indicated for use in the treatment of reversible airway obstruction. Pharmaceutical compositions containing these compounds are also described, especially compositions in which the active ingredient is in powder form with a mass median diameter of from 0.1 to 10 microns. British Patent Application No 2157291A describes the particular utility of the disodium salt of one of these compounds, 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)quinoline-2,8-dicarboxylic acid, in the treatment of reversible airway obstruction. Also described are powdered aerosol compositions of this salt for administration to the lung and physical forms of the salt which are especially suitable for formulation in this way.
BRIEF SUMMARY OF THE INVENTION
We have now surprisingly found that when it is administered in aqueous solution the same compound is efficacious in the treatment of a variety of disorders of the eye, notably conjunctivitis, as well as in the treatment of certain disorders associated with other organs.
Thus, according to the invention there is provided a method of treatment of a condition selected from the group comprising:
conjunctivitis, keratitis, ‘allergic eyes’, adenovirus infections, corneal homograft rejection, anterior uveitis;
nasal polyps, vasomotor rhinitis, allergic manifestations of the nasopharynx;
reversible obstructive airways disease;
Crohn's disease, distal colitis and proctitis, which method comprises administration to a patient suffering from such a condition of a therapeutically effective amount of an aqueous solution of 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano(3,2-g)quinoline-2,8-dicarboxylic acid or a pharmaceutically acceptable salt thereof.
By the term ‘conjunctivitis’ we mean inflammatory disorders of the conjunctiva commonly characterised by photophobia and irritation. The condition may be bacterial or vital and encompasses a number of specific types of conjunctivitis; for instance, seasonal allergic conjunctivitis, perennial allergic conjunctivitis, vernal catarrh (vernal kerato-conjunctivitis) , ‘irritable eye’ or ‘non-specific conjunctivitis’, Herpes Simplex Conjunctivitis, Herpes Zoster Conjunctivitis and phlyctenular conjunctivitis.
Similarly, by the term ‘keratitis’ we mean inflammation of the cornea which may involve its superficial surface (‘superficial keratitis’ including the localised form known as ‘corneal ulceration’) or be confined to the deeper layers (‘interstitial keratitis’). Other particular forms of keratitis which may be mentioned include Herpes Simplex Keratitis and Herpes Zoster Keratitis.
Proctitis includes chronic (ie ulcerative) and non-specific proctitis.
REFERENCES:
patent: 4328341 (1982-05-01), Raphael et al.
patent: 4419352 (1983-12-01), Cox et al.
patent: 4474787 (1984-10-01), Cairns et al.
patent: 4698345 (1987-10-01), Dicker et al.
patent: 4760072 (1988-07-01), Brown et al.
patent: 4849427 (1989-07-01), Nassim et al.
patent: 4866072 (1989-09-01), Edwards et al.
patent: 4868192 (1989-09-01), Totten et al.
patent: 2022078 (1979-12-01), None
patent: 2157291 (1985-04-01), None
patent: 0004722 (1983-01-01), None
Patel, K.R. “Dose-Response Study of Sodium Cromoglycate in Exercise-Induced Asthma”, Thorax, vol. 37, pp. 663-666.*
Br. J. Clin. Pharmac. vol. 24, Oct. 1987, pp. 493-501, M.G. Neale, et al “The Pharmacokinetics of Nedocromil Sodium, a New Drug for the kinetics of Nedocromil Sodium, a New Drug for the Treatment of Reversible Obstructive Airways Disease, in Human Volunteers and Patients with Reversible Obstructive Airways Disease”.*
J. Med. Chem. vol. 28, No. 12, 1985, pp. 1832-1842, American Chemical Society, H. Cairns, et al., New Antiallergic Pyrano (3,2-g) quinoline 2,8dicarboxylic Acids with Potential for the Topical Treatment of Asthma.*
J. Allergy Clin. Immunol. vol. 79, No. 1, Feb. 19-25, 1987, p. 186, abstract 247, Schwartz et al. “Efficacy of nedocromil sodium . . . ragweed seasonal allergic rhinitis (SAR)”.*
J. Allergy Clin. Immuno. vol. 80, No. 2, Aug., 1987, pp. 218-222, Corrado et al., “The effect of nedocromil sodium on nasal provocation with allergen.”*
J. Allergy Clin. Imunol., vol. 81, No. 3, Mar. 1988, pp. 570-574 Ruhno et al. “Intranasal nedocromil sodium in the treatment of ragweed-allergic rhinitis.”*
Invest. Ophtalmol. Visual Sci. vol. 29, May 1-6, 1988, p. 229, Stockwell et al, “Double blind group comparative trial of 2% nedocromil . . . seasonal allergic conjunctivitis.”*
Pharmazie, vol. 37, No. 4, 1982, pp. 261-263 Pohloudek-Fabini et al, “Zur Stabilitat der Phenylquecksilbersalze.”*
Journal of Pharmaceutical Sciences, vol. 65, No. 4, Apr. 1976, pp. 628-630, Grady, et al, “Testing of heat sealing by thermal analysis.”*
R. Voight, “Lehrbuch der pharmazeutischen Technologie”, 5th edition, 1984, pp. 554-557, Verlag Chemie, Weinheim, D.E.*
P.H. List: “Arzneiformenlehre” Chapter Konservierungmittel pp. 369-373, 1976.*
P.H. List: “Arzneiformenlehre” Chapter Augenarzneien pp. 400-410, 1976.*
R. Voight: “Lehrbuch der pharmazeutischen Technologie” Chapter 27 Augentropfen, pp. 459-467, 1975.*
Eur. J. Respir. Dis. (Suppl. 147) 1986, pp. 120-131, R.M. Auty: “The Clinical development of a new agent for the treatment of airway inflammation, nedocromil sodium (Tilade).”
Clark Andrew R.
Ratcliffe Julia H.
Wright Paul
Coudert Brothers LLP
Fisons plc
Hokanson, Esq. Jon
Joynes Robert M.
Page Thurman K.
LandOfFree
Pharmaceutical compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3313826